Brief: Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial
02/04/2025 13:08
April 2 (Reuters) - Tiziana Life Sciences Ltd TLSA.O: TIZIANA LIFE SCIENCES ANNOUNCES JOHNS HOPKINS UNIVERSITY COMMENCES DOSING NASAL FORALUMAB IN PHASE 2 MULTIPLE SCLEROSIS CLINICAL TRIAL Source text: ID:nGNX5Lwr9l Further company coverage: TLSA.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study